Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Hutchinson

Showing results (1-10 of 205) with videos related to

Pageof 21
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 2, 2011
Relapses do not matter in relation to long-term disability: commentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 8, 2011
Truly benign multiple sclerosis is rare: let's stop fooling ourselves--commentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 28, 2012
Rehabilitation therapy in MS: a short-term, expensive, placebo: commentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2013
In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 20, 2013
The best clinical paper on multiple sclerosis in 2012: commentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 27, 2013
Evoked potentials are of little use in the diagnosis or monitoring of MS: commentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 27, 2016
Integrated multidisciplinary clinics should be the gold standard in managing progressive MS - CommentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2016
Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: CommentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 7, 2015
Multiple sclerosis relapse phenotype is an important, neglected determinant of disease-outcome: CommentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 31, 2015
Neurodegeneration in multiple sclerosis is a process separate from inflammation: NoMichael Hutchinson
Pageof 21

Showing results (1-10 of 205) with videos related to

Sort By:
Pageof 21
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 2, 2011
Relapses do not matter in relation to long-term disability: commentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 8, 2011
Truly benign multiple sclerosis is rare: let's stop fooling ourselves--commentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 28, 2012
Rehabilitation therapy in MS: a short-term, expensive, placebo: commentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2013
In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 20, 2013
The best clinical paper on multiple sclerosis in 2012: commentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 27, 2013
Evoked potentials are of little use in the diagnosis or monitoring of MS: commentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 27, 2016
Integrated multidisciplinary clinics should be the gold standard in managing progressive MS - CommentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2016
Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: CommentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 7, 2015
Multiple sclerosis relapse phenotype is an important, neglected determinant of disease-outcome: CommentaryMichael Hutchinson
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 31, 2015
Neurodegeneration in multiple sclerosis is a process separate from inflammation: NoMichael Hutchinson
Pageof 21